Rezolute, Inc.’s (NASDAQ: RZLT) stock price is steadily moving higher in 2025 and is expected to continue its run because of what adds up to a rapidly improving outlook. Its lead pharmaceutical candidate, Ersodetug, was granted the FDA’s Breakthrough Therapy designation, which puts it on a fast track for approval.
The drug is set up for two Phase III trials, which are currently enrolling patients or have patients enrolled and ready to start.
